{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:26:15Z","timestamp":1789691175013,"version":"4.0.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with an incidence of 0.1 to 0.2\/100\u2009000\/y. Compared with the more common subtypes of classical Hodgkin lymphoma, NLPHL is characterized by distinct pathological and clinical features. Histologically, the disease-defining lymphocyte predominant cells consistently express CD20 but lack CD30. Clinically, NLPHL mostly has a rather indolent course, and patients usually are diagnosed in early stages. The prognosis of early-stage NLPHL is excellent, with progression-free survival and overall survival rates exceeding 90% after involved-field radiotherapy (IF-RT) alone (stage IA) or combined modality treatment consisting of a brief chemotherapy with 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by IF-RT (early stages other than stage IA). In contrast, patients with advanced disease at diagnosis tend to relapse either with NLPHL histology or with histological transformation into aggressive B-cell non-Hodgkin lymphoma despite more aggressive first-line treatment with 6 to 8 cycles of multiagent chemotherapy. However, even NLPHL patients with multiple relapses successfully respond to salvage therapy in many cases. Salvage therapies range from single-agent anti-CD20 antibody treatment to high-dose chemotherapy followed by autologous stem cell transplantation. Treatment at disease recurrence should be chosen on the basis of various factors, including histology at relapse, time to relapse, extent of disease at relapse, and prior treatment. Because death among NLPHL patients is more often caused by therapy-related late effects than lymphoma-related complications, optimizing the risk-benefit ratio of treatment by decreasing toxicity whenever possible is the major goal of clinical research in this disease.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.324","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"324-328","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":58,"title":["Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management"],"prefix":"10.1182","volume":"2017","author":[{"given":"Dennis A.","family":"Eichenauer","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany; and"},{"name":"German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany; and"},{"name":"German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"suppl 1","key":"2019111705365061400_B1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hon.2067","article-title":"VII. Management of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"31","author":"Eichenauer","year":"2013","journal-title":"Hematol Oncol"},{"key":"2019111705365061400_B2","doi-asserted-by":"crossref","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation","author":"Fan","year":"2003"},{"issue":"26","key":"2019111705365061400_B3","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111705365061400_B4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1084\/jem.20080809","article-title":"Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis","volume":"205","author":"Brune","year":"2008","journal-title":"J Exp Med"},{"issue":"11","key":"2019111705365061400_B5","doi-asserted-by":"crossref","first-page":"e78812","DOI":"10.1371\/journal.pone.0078812","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma and T cell\/histiocyte rich large B cell lymphoma\u2014endpoints of a spectrum of one disease?","volume":"8","author":"Hartmann","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"2019111705365061400_B6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111705365061400_B7","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2015-08-665505","article-title":"Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution","volume":"127","author":"Kenderian","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111705365061400_B8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"2019111705365061400_B9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111705365061400_B10","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111705365061400_B11","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ijrobp.2008.09.049","article-title":"Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin\u2019s lymphoma","volume":"74","author":"Haas","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"2019111705365061400_B12","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"issue":"20","key":"2019111705365061400_B13","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children\u2019s Oncology Group","volume":"34","author":"Appel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111705365061400_B14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"2019111705365061400_B15","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111705365061400_B16","first-page":"275","article-title":"Long-term outcome of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD7-HD15 trials: an analysis from the German Hodgkin Study Group (GHSG) [abstract]","volume":"102","author":"Eichenauer","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2019111705365061400_B17","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ejca.2011.10.018","article-title":"Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin\u2019s lymphoma\u2014an Anglo-French collaborative report","volume":"48","author":"Shankar","year":"2012","journal-title":"Eur J Cancer"},{"issue":"7","key":"2019111705365061400_B18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111705365061400_B19","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111705365061400_B20","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood.V126.23.3863.3863","article-title":"Outcomes of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) vs. classical Hodgkin lymphoma (cHL) at Princess Margaret Cancer Centre","volume":"126","author":"Ames","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111705365061400_B21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111705365061400_B22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111705365061400_B23","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111705365061400_B24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/leu.2015.321","article-title":"Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin Study Group","volume":"30","author":"Eichenauer","year":"2016","journal-title":"Leukemia"},{"issue":"22","key":"2019111705365061400_B25","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V128.22.922.922","article-title":"Relapsed nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group (GHSG)","volume":"128","author":"Eichenauer","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111705365061400_B26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/blood.V128.22.514.514","article-title":"Relapsed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): high efficacy of high dose chemotherapy and autologous stem cell transplantation (HDC auto-SCT). A study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"128","author":"Akhtar","year":"2016","journal-title":"Blood"},{"key":"2019111705365061400_B27","author":"Karuturi","year":"2013"},{"issue":"3","key":"2019111705365061400_B28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/324\/1251060\/hem00045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/324\/1251060\/hem00045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T05:37:03Z","timestamp":1573969023000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/324\/21197\/Nodular-lymphocytepredominant-Hodgkin-lymphoma-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.324","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}